SOAT1 and hepatocellular carcinoma: In conclusion, EPHX1 inhibits the anti-tumor effect of regorafenib by activating the JAK/STAT pathway, and the JAK/STAT inhibitor HY-N-1447 can reverse the resistance induced by EPHX1, suggesting that EPHX1 targeting JAK/STAT is an important mechanism of regorafenib resistance in HCC.